324 related articles for article (PubMed ID: 28394532)
1. [Phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: past, present and future].
Gamidov SI; Ovchinnikov RI; Popova AY; Izhbaev SK
Urologiia; 2017 Apr; (1):103-107. PubMed ID: 28394532
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase Type-5 Inhibitor Prescription Patterns in the United States Among Men With Erectile Dysfunction: An Update.
Mulhall JP; Chopra I; Patel D; Hassan TA; Tang WY
J Sex Med; 2020 May; 17(5):941-948. PubMed ID: 32144034
[TBL] [Abstract][Full Text] [Related]
3. Risk-benefit assessment of oral phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction: a multiple criteria decision analysis.
Hsu JC; Tang DH; Lu CY
Int J Clin Pract; 2015 Apr; 69(4):436-43. PubMed ID: 25311239
[TBL] [Abstract][Full Text] [Related]
4. Useful Implications of Low-dose Long-term Use of PDE-5 Inhibitors.
Mostafa T
Sex Med Rev; 2016 Jul; 4(3):270-284. PubMed ID: 27871960
[TBL] [Abstract][Full Text] [Related]
5. PDE-5 inhibitors: clinical points.
Doumas M; Lazaridis A; Katsiki N; Athyros V
Curr Drug Targets; 2015; 16(5):420-6. PubMed ID: 25392015
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of phosphodiesterase type 5 (PDE5) inhibitors in treating erectile dysfunction after bilateral nerve-sparing radical prostatectomy.
Cui Y; Liu X; Shi L; Gao Z
Andrologia; 2016 Feb; 48(1):20-8. PubMed ID: 25684196
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction in Patients with Spinal Cord Trauma: Systematic Review and Meta-Analysis.
García-Perdomo HA; Echeverría-García F; Tobías A
Urol Int; 2017; 98(2):198-204. PubMed ID: 27509143
[TBL] [Abstract][Full Text] [Related]
8. Lodenafil.
Alshehri YM; Al-Majed AA; Attwa MW; Bakheit AH
Profiles Drug Subst Excip Relat Methodol; 2022; 47():113-147. PubMed ID: 35396013
[TBL] [Abstract][Full Text] [Related]
9. [Phosphodesterase type 5 inhibitors clinical efficiency and role in therapy for erectile dysfunction].
Shodmonova ZR; Gafarov RR; Allazov SA; Giyasov SI
Urologiia; 2021 May; (2):135-140. PubMed ID: 33960173
[TBL] [Abstract][Full Text] [Related]
10. Patient diagnosed with chronic erectile dysfunction refractory to PDE 5 Inhibitor therapy reports improvement in function after hyperbaric oxygen therapy.
Cormier J; Theriot M
Undersea Hyperb Med; 2016; 43(4):463-465. PubMed ID: 28763176
[TBL] [Abstract][Full Text] [Related]
11. An open-label, multicenter, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in Chinese men naïve to phosphodiesterase 5 inhibitor therapy.
Bai WJ; Li HJ; Dai YT; He XY; Huang YR; Liu JH; Sorsaburu S; Ji C; Jin JJ; Wang XF
Asian J Androl; 2015; 17(1):61-7. PubMed ID: 25370206
[TBL] [Abstract][Full Text] [Related]
12. [Current role of sildenafil in the management of erectile dysfunction].
Akhvlediani ND; Matyukhov IP
Urologiia; 2018 May; (2):142-146. PubMed ID: 29901310
[TBL] [Abstract][Full Text] [Related]
13. The first-generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue.
Zucchi A; Costantini E; Scroppo FI; Silvani M; Kopa Z; Illiano E; Petrillo MG; Cari L; Nocentini G
Andrology; 2019 Nov; 7(6):804-817. PubMed ID: 31350821
[TBL] [Abstract][Full Text] [Related]
14. Adverse reactions of PDE5 inhibitors: An analysis of the World Health Organization pharmacovigilance database.
Lui JL; Shaw NM; Abbasi B; Hakam N; Breyer BN
Andrology; 2023 Oct; 11(7):1408-1417. PubMed ID: 36905319
[TBL] [Abstract][Full Text] [Related]
15. Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction.
Briganti A; Salonia A; Deho' F; Zanni G; Barbieri L; Rigatti P; Montorsi F
World J Urol; 2005 Dec; 23(6):374-84. PubMed ID: 16273417
[TBL] [Abstract][Full Text] [Related]
16. Use of phosphodiesterase type 5 inhibitors in assistive living and home care settings.
Iannino-Renz R; Mager D
Appl Nurs Res; 2015 Aug; 28(3):251-3. PubMed ID: 26060141
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy and tolerance of PDE-5 in the treatment of erectile dysfunction in schizophrenic patients: A literature review].
Bacconi L; Gressier F
Encephale; 2017 Feb; 43(1):55-61. PubMed ID: 27658991
[TBL] [Abstract][Full Text] [Related]
18. Phosphodiesterase 5 inhibitors in male sexual dysfunction.
Kuthe A
Curr Opin Urol; 2003 Sep; 13(5):405-10. PubMed ID: 12917517
[TBL] [Abstract][Full Text] [Related]
19. Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis.
Gong B; Ma M; Xie W; Yang X; Huang Y; Sun T; Luo Y; Huang J
Int Urol Nephrol; 2017 Oct; 49(10):1731-1740. PubMed ID: 28741090
[TBL] [Abstract][Full Text] [Related]
20. Erectile dysfunction drugs altered the activities of antioxidant enzymes, oxidative stress and the protein expressions of some cytochrome P450 isozymes involved in the steroidogenesis of steroid hormones.
Sheweita SA; Meftah AA; Sheweita MS; Balbaa ME
PLoS One; 2020; 15(11):e0241509. PubMed ID: 33166302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
